Related Experiment Video

Updated: Jul 17, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Arsenic trioxide and acute promyelocytic leukemia: clinical and biological

Z Chen1, W L Zhao, Z X Shen

  • 1Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, 197 Rui Jin Road II, 200025 Shanghai, People's Republic of China. zchen@stn.sh.cn

Current Topics in Microbiology and Immunology
|January 16, 2007
PubMed

Insights

Arsenic trioxide is an effective treatment for acute promyelocytic leukemia, both newly diagnosed and relapsed. It works by targeting the PML-RARalpha protein, demonstrating a novel molecular targeted cancer therapy approach.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Acute promyelocytic leukemia (APL) is a distinct subtype of leukemia.
  • Targeted therapies are revolutionizing cancer treatment.

Purpose of the Study:

  • To evaluate arsenic trioxide as a treatment for acute promyelocytic leukemia.
  • To investigate the synergistic effects of arsenic trioxide with all-trans retinoic acid.
  • To elucidate the molecular mechanisms of arsenic trioxide in APL treatment.

Main Methods:

  • Clinical trials assessing arsenic trioxide efficacy in newly diagnosed and relapsed APL.
  • Combination therapy studies with all-trans retinoic acid.
  • Molecular analyses to identify arsenic's protein targets.

Main Results:

  • Arsenic trioxide demonstrates significant efficacy in treating both newly diagnosed and relapsed APL.
  • A synergistic therapeutic effect was observed when arsenic trioxide was combined with all-trans retinoic acid.
  • Arsenic trioxide was found to target and degrade the PML-RARalpha oncoprotein.

Conclusions:

  • Arsenic trioxide is a valuable therapeutic agent for acute promyelocytic leukemia.
  • The combination of arsenic trioxide and all-trans retinoic acid offers enhanced efficacy.
  • Arsenic trioxide represents a successful example of molecular targeted cancer therapy by targeting PML-RARalpha.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...